Yüklüyor......
The Ibr‐7 derivative of ibrutinib exhibits enhanced cytotoxicity against non‐small cell lung cancer cells via targeting of mTORC1/S6 signaling
Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B‐cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia. However, the anti‐cancer activity of ibrutinib against solid tumors, such as non‐small cell lung cancer (NSCL...
Kaydedildi:
| Yayımlandı: | Mol Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6441926/ https://ncbi.nlm.nih.gov/pubmed/30663221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12454 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|